



truscreen
a world without
cervical cancer

NZX Announcement

21 September 2020

Recording of Truscreen Group Limited ASM Virtual Meeting

The Annual Shareholder Meeting of Truscreen Group Limited (NZX:TRU) was held online on 10 September 2020 on Link Market Services virtual platform.

A recording is available online at:

<https://vimeo.com/456400050/a1455ff0d2>

-ENDS-

For more information, visit www.truscreen.com or contact:

Tony Ho
Chairman
tonyho@truscreen.com

Victoria Potarina
Chief Executive Officer
victoriapotarina@truscreen.com

About TruScreen:

TruScreen cervical cancer screening device [offers the latest technology](#) in cervical screening, providing real-time, accurate detection of precancerous and cancerous cervical cells to help improve the health and well-being of women around the world.

TruScreen's real-time cervical cancer technology utilises a digital wand which is placed on the surface of the cervix to measure electrical and optical signals from the surrounding tissues. A sophisticated proprietary algorithm framework is utilised to detect pre-cancerous change, or cervical intra-epithelial neoplasia (CIN), by optical and electrical measurement of cervical tissue.

TruScreen offers an alternative approach to cervical screening, [resolving many of the ongoing issues](#) with conventional Pap tests, including failed samples, poor patient follow-up, patient discomfort and the need for supporting laboratory infrastructure. As such, TruScreen's target [market](#) is low and middle-income countries where no large-scale cervical cancer screening programs and infrastructure are in place, such as China, Mexico, Africa, Russia and India. TruScreen's cervical cancer screening device is CE-marked and certified for use throughout Europe and CFDA approved for sale in China. The global market potential for TruScreen is significant.